Kodiak Sciences stock triples as Zenkuda matches Eylea in Phase 3 trial
Kodiak Sciences shares surged nearly 178% after its Phase 3 Daybreak trial results showed that both Zenkuda and tabirafusp-ted matched the efficacy of aflibercept (Eylea) for wet age-related macular degeneration. The company plans to file for FDA approval of Zenkuda in the fourth quarter of 2026, citing data that allows for extended dosing intervals.